|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/24 Astria Therapeutics, Inc. 10-K 12/31/23 80:11M Toppan Merrill/FA2 |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.37M
2: EX-10.18 Material Contract HTML 225K
3: EX-10.19 Material Contract HTML 675K
4: EX-21.1 Subsidiaries List HTML 23K
5: EX-23.1 Consent of Expert or Counsel HTML 22K
10: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 41K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
16: R1 Document and Entity Information HTML 93K
17: R2 Consolidated Balance Sheets HTML 110K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
19: R4 Consolidated Statements of Operations HTML 72K
20: R5 Consolidated Statements of Comprehensive Loss HTML 45K
21: R6 Consolidated Statements Comprehensive Loss HTML 24K
(Parenthetical)
22: R7 Consolidated Statements of Stockholders' Equity HTML 85K
23: R8 Consolidated Statements of Cash Flows HTML 94K
24: R9 Organization and Operations HTML 36K
25: R10 Summary of Significant Accounting Policies HTML 96K
26: R11 Fair Value Measurements HTML 107K
27: R12 Short-Term Investments HTML 76K
28: R13 Accrued Expenses HTML 40K
29: R14 Commitments HTML 33K
30: R15 Stockholders' Equity HTML 63K
31: R16 Stock Incentive Plans HTML 82K
32: R17 Income Taxes HTML 80K
33: R18 Defined Contribution Benefit Plan HTML 25K
34: R19 Subsequent Events HTML 28K
35: R20 Summary of Significant Accounting Polices HTML 145K
(Polices)
36: R21 Summary of Significant Accounting Policies HTML 59K
(Tables)
37: R22 Fair Value Measurements (Tables) HTML 105K
38: R23 Short-Term Investments (Tables) HTML 73K
39: R24 Accrued Expenses (Tables) HTML 40K
40: R25 Commitments (Tables) HTML 31K
41: R26 Stockholders' Equity (Tables) HTML 61K
42: R27 Stock Incentive Plans (Tables) HTML 73K
43: R28 Income Taxes (Tables) HTML 73K
44: R29 Organization and Operations - December 2022 HTML 40K
Financing (Details)
45: R30 Organization and Operations - License Agreement HTML 41K
(Details)
46: R31 Organization and Operations - October 2023 HTML 44K
Financing (Details)
47: R32 Organization and Operations - Liquidity (Details) HTML 59K
48: R33 Summary of Significant Accounting Polices - Cash HTML 34K
and Cash Equivalents and Restricted Cash (Details)
49: R34 Summary of Significant Accounting Polices - Fair HTML 33K
Value of Financial Instruments (Details)
50: R35 Summary of Significant Accounting Policies - HTML 31K
Stock-Based Compensation (Details)
51: R36 Summary of Significant Accounting Policies - Net HTML 39K
Loss Per Share (Details)
52: R37 Summary of Significant Accounting Policies - HTML 24K
Segment Information (Details)
53: R38 Summary of Significant Accounting Policies - HTML 33K
Preferred Stock Discount (Details)
54: R39 Summary of Significant Accounting Policies - HTML 24K
Financing Costs (Details)
55: R40 Summary of Significant Accounting Policies - HTML 31K
License Agreement (Details)
56: R41 Fair Value Measurements - Fair value hierarchy HTML 58K
(Details)
57: R42 Fair Value Measurements - Warrant liability HTML 28K
(Details)
58: R43 Short-Term Investments (Details) HTML 50K
59: R44 Accrued Expenses (Details) HTML 34K
60: R45 Commitments (Details) HTML 36K
61: R46 Stockholders' Equity - Preferred Stock (Details) HTML 39K
62: R47 Stockholders' Equity - Common Stock Outstanding HTML 36K
Warrants (Details)
63: R48 Stockholders' Equity - Common Stock (Details) HTML 32K
64: R49 Stockholders' Equity - Shares Reserved for Future HTML 40K
Issuance (Details)
65: R50 Stock Incentive Plans - Summary of Plans (Details) HTML 38K
66: R51 Stock Incentive Plans - Stock option activity HTML 94K
(Details)
67: R52 Stock Incentive Plans - Stock-Based Compensation HTML 37K
Expense (Details)
68: R53 Stock Incentive Plans - Inducement plan (Details) HTML 48K
69: R54 Income Taxes - Reconciliation (Details) HTML 42K
70: R55 Income Taxes - Deferred tax assets (Details) HTML 53K
71: R56 Income Taxes - Operating Loss Carryforwards HTML 34K
(Details)
72: R57 Defined Contribution Benefit Plan (Details) HTML 25K
73: R58 Subsequent Events (Details) HTML 44K
74: R59 Pay vs Performance Disclosure HTML 34K
75: R60 Insider Trading Arrangements HTML 28K
77: XML IDEA XML File -- Filing Summary XML 133K
80: XML XBRL Instance -- atxs-20231231x10k_htm XML 1.50M
76: EXCEL IDEA Workbook of Financial Report Info XLSX 92K
12: EX-101.CAL XBRL Calculations -- atxs-20231231_cal XML 135K
13: EX-101.DEF XBRL Definitions -- atxs-20231231_def XML 536K
14: EX-101.LAB XBRL Labels -- atxs-20231231_lab XML 1.13M
15: EX-101.PRE XBRL Presentations -- atxs-20231231_pre XML 819K
11: EX-101.SCH XBRL Schema -- atxs-20231231 XSD 148K
78: JSON XBRL Instance as JSON Data -- MetaLinks 456± 633K
79: ZIP XBRL Zipped Folder -- 0001410578-24-000127-xbrl Zip 529K
 | Download this Microsoft® Excel® .xlsx workbook |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/09/24 Astria Therapeutics, Inc. 10-Q 3/31/24 56:4.8M Toppan Merrill/FA2 3/04/24 Astria Therapeutics, Inc. 424B5 1:348K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/20/23 Astria Therapeutics, Inc. 8-K:5,9 12/14/23 11:279K Toppan Merrill/FA 10/12/23 Astria Therapeutics, Inc. 8-K:1,8,9 10/11/23 15:775K Toppan Merrill/FA 8/07/23 Astria Therapeutics, Inc. 10-Q 6/30/23 56:5.2M Toppan Merrill/FA2 6/06/23 Astria Therapeutics, Inc. 8-K:5,9 6/02/23 12:584K Toppan Merrill/FA 5/12/22 Astria Therapeutics, Inc. 10-Q 3/31/22 66:5.6M Toppan Merrill/FA 3/10/22 Astria Therapeutics, Inc. 10-K 12/31/21 78:12M Toppan Merrill/FA 2/22/22 Astria Therapeutics, Inc. 8-K:5,9 2/17/22 12:339K Toppan Merrill/FA 3/11/21 Astria Therapeutics, Inc. S-8 3/11/21 4:173K Toppan Merrill/FA 3/11/21 Astria Therapeutics, Inc. 10-K 12/31/20 10:1.8M Toppan Merrill/FA 1/29/21 Astria Therapeutics, Inc. 8-K:1,2,3,5 1/28/21 7:5.8M Toppan Merrill/FA 5/13/15 Astria Therapeutics, Inc. S-1 24:8M Toppan Merrill-FA |